<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title> Analysis of Adverse Event</title>

<script src="site_libs/header-attrs-2.28/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cerulean.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<link href="site_libs/pagedtable-1.1/css/pagedtable.css" rel="stylesheet" />
<script src="site_libs/pagedtable-1.1/js/pagedtable.js"></script>
<script src="site_libs/kePrint-0.0.1/kePrint.js"></script>
<link href="site_libs/lightable-0.0.1/lightable.css" rel="stylesheet" />
<link href="site_libs/htmltools-fill-0.5.8.1/fill.css" rel="stylesheet" />
<script src="site_libs/htmlwidgets-1.6.4/htmlwidgets.js"></script>
<script src="site_libs/plotly-binding-4.10.4.9000/plotly.js"></script>
<script src="site_libs/typedarray-0.1/typedarray.min.js"></script>
<link href="site_libs/crosstalk-1.2.1/css/crosstalk.min.css" rel="stylesheet" />
<script src="site_libs/crosstalk-1.2.1/js/crosstalk.min.js"></script>
<link href="site_libs/plotly-htmlwidgets-css-2.11.1/plotly-htmlwidgets.css" rel="stylesheet" />
<script src="site_libs/plotly-main-2.11.1/plotly-latest.min.js"></script>
<link href="site_libs/font-awesome-6.4.2/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.4.2/css/v4-shims.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Zehui Bai</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="index.html">
    <span class="fa fa-home"></span>
     
    Home
  </a>
</li>
<li>
  <a href="02-Clinical_Experience.html">
    <span class="fa fa-user"></span>
     
    Clinical Experience
  </a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-sliders"></span>
     
    Sample Size
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="03-SSC-Everything-to-Know-About-Sample-Size-Determination.html">Everything to Know About Sample Size Determination</a>
    </li>
    <li>
      <a href="03-SSC-Choosing-the-Effect-Size-for-Sample-Size-Calculations.html">Choosing the Effect Size</a>
    </li>
    <li>
      <a href="03-SSC-Biosimilar-Trials.html">Statistical Considerations for the Design and Analysis of Biosimilar Trials</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-and-Power-for-Non-Parametric-Analysis.html">Sample Size and Power for Non-Parametric Analysis</a>
    </li>
    <li>
      <a href="03-SSC-Power-for-Complex-Hypotheses.html">Power for Complex Hypotheses</a>
    </li>
    <li>
      <a href="03-SSC-Alternatives-to-Power.html">Bayesian methods - Alternatives to Power</a>
    </li>
    <li>
      <a href="03-SSC-Sample-Size-for-Pilot-Studies.html">Sample Size for Pilot Studies</a>
    </li>
    <li>
      <a href="03-SSC-Case-Continuous-Endpoint.html">Sample Size Determination for Continuous Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Categorical-Endpoint.html">Sample Size Determination for Categorical Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Survival-Endpoint.html">Sample Size Determination for Survival Endpoint</a>
    </li>
    <li>
      <a href="03-SSC-Case-Repeated-Measures.html">Sample Size Determination for Repeated Measures</a>
    </li>
    <li>
      <a href="03-SSC-IA-Sequential-Design.html">Statistical Considerations for Group Sequential Design</a>
    </li>
    <li>
      <a href="03-SSC-IA-Adaptive-Design.html">Statistical Considerations for Adaptive Design</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-pencil-square-o"></span>
     
    Study Design
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="04-Design-Estimands.html">Estimands and Sensitivity Analyses</a>
    </li>
    <li>
      <a href="04-Design-Dose-Escalation-and-Stratification-Designs.html">Dose Escalation and Stratification Designs in Early Oncology Development</a>
    </li>
    <li>
      <a href="04-Design-Phase-I-Trials---Design-Considerations.html">Phase I Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-II-Trials---Design-Considerations.html">Phase II Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-III-Trials---Design-Considerations.html">Phase III Trials - Design Considerations</a>
    </li>
    <li>
      <a href="04-Design-Phase-IV-Trials---Design-Considerations.html">Phase IV Trials - Design Considerations for Post Marketing Surveillance</a>
    </li>
    <li>
      <a href="04-Design-Design-and-Monitoring-of-Adaptive-Clinical-Trials.html">Design and Monitoring of Adaptive Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Design-and-Evaluation-of-Complex-Sequential-Trials.html">Design and Evaluation of Complex Sequential Analysis Trials</a>
    </li>
    <li>
      <a href="04-Design-Design-and-Evaluation-of-Diagnostic-Study.html">Design and Evaluation of Diagnostic Study</a>
    </li>
    <li>
      <a href="04-Design-Hierarchical-composite-endpoints.html">Hierarchical Composite Endpoints</a>
    </li>
    <li>
      <a href="04-Design-Externally-Controlled-Trials.html">Considerations for the Design and Conduct of Externally Controlled Trials</a>
    </li>
    <li>
      <a href="04-Design-Noninferiority-Trials.html">Noninferiority Trials</a>
    </li>
    <li>
      <a href="04-Design-Bioequivalence-and-Biosimilar-Trials.html">Bioequivalence and Biosimilar Trials</a>
    </li>
    <li>
      <a href="04-Design-Exploring-Survival-Analysis-Designs-for-Clinical-Trials.html">Exploring Survival Analysis Designs for Clinical Trials</a>
    </li>
    <li>
      <a href="04-Design-Projecting-How-Long-Your-Trial-Will-Take.html">Projecting How Long Your Trial Will Take</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-line-chart"></span>
     
    Data Visualization
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="05-Plot-Adverse-Event.html">Adverse Event Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Laboratory-Data.html">Laboratory Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Time-To-Event.html">Time to Event Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-PRO-Data.html">Patient Reported Outcome Data Visualization</a>
    </li>
    <li>
      <a href="05-Plot-SSC-and-Power-Calculation.html">Sample Size and Power Calculations Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Correlation.html">Correlation Visualization</a>
    </li>
    <li>
      <a href="05-Plot-Model-Table.html">Clinical Data and Model visualization</a>
    </li>
    <li>
      <a href="05-Plot-ScatterPlot.html">Scatter and Line Plot</a>
    </li>
    <li>
      <a href="05-Plot-BarPlot.html">Bar Chart</a>
    </li>
    <li>
      <a href="05-Plot-PieChart.html">Pie Chart</a>
    </li>
    <li>
      <a href="05-Plot-BoxPlot.html">Box Plot</a>
    </li>
    <li>
      <a href="05-Plot-Histogram.html">Histogram</a>
    </li>
    <li>
      <a href="05-Plot-Forest-Plot.html">Forest Plot</a>
    </li>
    <li>
      <a href="05-Plot-Flow-Chart.html">Flow Chart</a>
    </li>
    <li>
      <a href="05-Plot-Some-Interesting.html">Some Interesting Plots</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-line-chart"></span>
     
    Statistical Analysis
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="06-Analysis-Linear-Regression.html">Linear Regression</a>
    </li>
    <li>
      <a href="06-Analysis-Logistic-Regression.html">Logistic Regression</a>
    </li>
    <li>
      <a href="06-Analysis-Mixed-Model.html">Mixed Model</a>
    </li>
    <li>
      <a href="06-Analysis-MMRM.html">Mixed Model Repeated Measures</a>
    </li>
    <li>
      <a href="06-Analysis-GEE.html">Generalized Estimating Equation</a>
    </li>
    <li>
      <a href="06-Analysis-ANOVA.html">Analysis of Variance</a>
    </li>
    <li>
      <a href="06-Analysis-Survival-Analysis.html">Survival Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-Survival-Competing-Risk.html">Survival Analysis - Competing Risk</a>
    </li>
    <li>
      <a href="06-Analysis-Missing-Data.html">Missing Data Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-MI-Implementation.html">Multiple Imputation Analysis</a>
    </li>
    <li>
      <a href="06-Analysis-PK-and-PD.html">PK and PD Analysis</a>
    </li>
  </ul>
</li>
<li>
  <a href="07-CV.html">
    <span class="fa fa-file-pdf-o"></span>
     
    CV
  </a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="mailto:zehuibai@outlook.com">
    <span class="fa fa-envelope-o"></span>
     
    Contact me
  </a>
</li>
<li>
  <a href="https://github.com/Zehuibai">
    <span class="fa fa-github"></span>
     
    GitHub
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore"><p><img src="logo.png"
style="width:3in" /><br />
Analysis of Adverse Event</p></h1>

</div>


<div id="statistical-analysis-of-aes" class="section level1">
<h1>Statistical Analysis of AEs</h1>
<p>Efficacy and safety are two crucial aspects of assessing the
risk-benefit ratio of a drug. When a drug’s efficacy meets the
regulatory requirements, its safety profile must also be within a
reasonable range. However, clinical trials sometimes reveal peculiar
adverse reactions that attract regulatory attention, such as
immune-related adverse events (irAEs) from PD-1/L1 inhibitors, bone
damage from BTK inhibitors, and bleeding events from EGFR inhibitors. In
such cases, sponsors are often required to conduct more in-depth
analyses to clarify the drug’s safety. Based on past clinical trial
experiences and literature, here have summarized some analytical methods
for adverse events that sponsors and regulatory bodies might require for
your reference.</p>
<div id="incidence" class="section level2">
<h2>Incidence</h2>
<p>Calculating the incidence rate is a fundamental requirement for AE
analysis. This includes overall incidence rates, incidence by preferred
terms (PT), standard of care (SOC), and by severity levels, including
AEs that lead to drug discontinuation, interruption of treatment, or
death.</p>
</div>
<div id="time-to-occurrence-and-duration" class="section level2">
<h2>Time to Occurrence and Duration</h2>
<p>The time from drug administration to the occurrence of an AE and the
duration of the AE are two important dimensions of AE analysis. If an AE
persists, it indicates that this type of AE tends to last long
clinically and may require the sponsor to explain how to manage and
ensure safety, especially for AEs of grade 3 or higher, which are of
greater concern. The following table displays a common summary
format:</p>
<p><img src="02_Plots/Visualization/AEs/AE_Time2Onset.png" />
<em>Source: John Shaik et al., PharmaSUG 2016.</em></p>
<p>The figure below demonstrates the use of Kaplan-Meier (KM) curves to
analyze the occurrence of AEs.</p>
<p><img src="02_Plots/Visualization/AEs/AE_KMPlot.png" /> <em>Source:
Kriss Harris et al., PhUSE 2017</em></p>
</div>
<div id="temporal-distribution-of-aes" class="section level2">
<h2>Temporal Distribution of AEs</h2>
<p>Analyzing the patterns of AE occurrence over different time periods.
For example, although an AE may occur rapidly, it might disappear
quickly or be transient, thus having a minimal impact. If a certain type
of AE continues throughout the medication period and is of a higher
CTCAE grade, it is likely drug-related and clinical considerations for
management are necessary.</p>
<p>The following figure shows the distribution over time of three types
of AEs in melanoma patients treated with Nivo+Ipi. It can be observed
that most skin-related AEs cease to appear after 3 months, and GI and
liver-related AEs significantly decrease after 6 months.</p>
<p><img
src="02_Plots/Visualization/AEs/AE_Temporal%20Distribution.png" /></p>
</div>
<div id="outcome-summary-of-adverse-events-aes" class="section level2">
<h2>Outcome Summary of Adverse Events (AEs)</h2>
<p>The outcome of an AE represents whether interventions against the AE
are effective. If there is no recovery, the duration of the AE will be
prolonged, indicating that effective intervention for this type of AE is
challenging.</p>
</div>
<div id="analysis-of-factors-influencing-aes" class="section level2">
<h2>Analysis of Factors Influencing AEs</h2>
<p>If the AEs in the experimental group are particularly prominent
(e.g., significantly more bleeding events or a higher mortality rate in
the experimental group compared to controls), regulatory bodies often
require an analysis of influencing factors. If clinical influencing
factors can be identified, measures can be taken to control them, also
indicating that the AEs are predictable.</p>
<p>Sometimes, to reduce the bias due to timing in between-group
comparisons, a landmark analysis strategy might be used, which excludes
patients who stopped treatment or died prematurely. For example,
patients who terminated treatment or died within two months may be
excluded.</p>
</div>
<div id="hazard-ratio-hr-of-ae-occurrence" class="section level2">
<h2>Hazard Ratio (HR) of AE Occurrence</h2>
<p>This is also a method for analyzing differences in AE characteristics
between two groups, using survival analysis to study the hazard ratio of
AE occurrence. The figure below shows the risk of irAEs in the
Keynote-054 study comparing Drug K with a placebo (HR = 5.0), indicating
that the risk of irAEs is significantly higher in the experimental
group.</p>
<p><img src="02_Plots/Visualization/AEs/AE_HR.png" /></p>
</div>
</div>
<div id="ae-visualization" class="section level1">
<h1>AE Visualization</h1>
<div id="relative-riskforest-plot" class="section level2">
<h2>Relative Risk/Forest Plot</h2>
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["Pbo"],"name":[1],"type":["int"],"align":["right"]},{"label":["Xan_Hi"],"name":[2],"type":["int"],"align":["right"]}],"data":[{"1":"44","2":"43"}],"options":{"columns":{"min":{},"max":[10]},"rows":{"min":[10],"max":[10]},"pages":{}}}
  </script>
</div>
<p><img src="05-Plot-Adverse-Event_files/figure-html/unnamed-chunk-1-1.png" width="960" /><img src="05-Plot-Adverse-Event_files/figure-html/unnamed-chunk-1-2.png" width="960" /><img src="05-Plot-Adverse-Event_files/figure-html/unnamed-chunk-1-3.png" width="960" /></p>
</div>
<div id="heat-map" class="section level2">
<h2>Heat Map</h2>
<p>Using a heatmap to display adverse event (AE) co-occurrence can be an
effective visual tool in medical research to identify and analyze
patterns of symptoms or side effects that frequently appear
together.</p>
<p>Heat maps are charts with values being represented by colors. The
intensity of the color is an indication of the number i.e. higher the
value more intense will be the color.</p>
<p><strong>HEAT MAP FOR NUMBER OF ADVERSE EVENTS PER TREATMENT PER
SYSTEM ORGAN CLASS (SOC):</strong></p>
<p>A heat map can be generated to visualize the number of adverse events
recorded per SOC per treatment. We will plot the treatments on x-axis
and the SOCs on y-axis. Each tile of the heat map will be colored as per
the number of events recorded for that particular combination. The color
of the tile will vary from yellow to red, with low counts shown in
yellow and high counts in red. The tiles with white color denote the
absence of events for a particular combination of SOC and treatment. The
number of events will be printed in either black or white as per a
predefined threshold; counts below or equal to the threshold will be
printed in black, remaining will be in white.</p>
<p>In this plot, we are able to see the number of events reported for
every SOC for all 5 arms. As seen in the legend, tiles with count less
than 100 are yellow with varying intensity as per the actual count for
that tile. For e.g. if we check the number of adverse events in the
gastrointestinal system for treatments X and Y, the count is 11 and 26
respectively. The color of the tile for Y is deeper than the tile for X.
The color starts changing from yellow to orange and then to red as the
number of events increases. This is observed in the “Psychiatric” SOC
counts, with 31 events Y has a yellow tile, 257 events lead to treatment
A having an orange tile and the treatment Z has a red tile due to the
311 events reported. Here the threshold for number of events has been
set to 100. We can quickly identify the SOCs with number of events
greater than 100 as they are printed in white. We can observe white
tiles for SOCs with no events for a particular treatment like
Reproductive system and treatment X.</p>
<p><img src="02_Plots/Visualization/AEs/AE_Heat%20Map%201.png" /></p>
<p><img src="05-Plot-Adverse-Event_files/figure-html/unnamed-chunk-2-1.png" width="960" /></p>
<p><strong>HEAT MAP FOR NUMBER OF SERIOUS AND NON SERIOUS ADVERSE EVENTS
PER SOC PER TREATMENT</strong></p>
<p>The adverse events are classified as either ‘Non Serious’ or
‘Serious’. We can plot the number of serious and non serious events
occurring per SOC per treatment as shown in the heat map below. In this
plot, both the counts will be displayed in the same tile and the color
of the tile will be decided by the maximum of the number of events if
both events are present.</p>
<p><img src="02_Plots/Visualization/AEs/AE_Heat%20Map%202.png" /></p>
<p><strong>HEAT MAP FOR NUMBER OF ADVERSE EVENTS PER TREATMENT PER
PREFERRED TERM (PT) FOR A SINGLE SOC</strong></p>
<p>As mentioned earlier, we can analyze the psychiatric disorders
further by generating a heat map of the events reported under this SOC
for all treatments. We will generate a heat map of all PTs with number
of reported events greater than 10.</p>
<p><img src="02_Plots/Visualization/AEs/AE_Heat%20Map%203.png" /></p>
<!-- sub <- subset(aeord,aeord$SOC=="PSYCHIATRIC") -->
<!-- tb4 <-aggregate(USUBJID~TRTA+AEDECOD, data=sub, FUN=function(x) c(ln=length(x))) -->
<!-- names(tb4)[names(tb4)=="USUBJID"]<- "OBS" -->
<!-- p3 <- ggplot(tb4[tb4$OBS>10,], (aes(x = TRTA, y = AEDECOD, fill = OBS))) + geom_raster() + -->
<!-- geom_text(aes(label = paste0("N=",round(OBS, 1)), color = OBS < 40), show.legend = -->
<!-- F,size=4)+ scale_fill_gradient(low="yellow",high="red",na.value="white")+ -->
<!-- scale_color_manual(values = c("FALSE" = "white", "TRUE" = "black")) + -->
<!-- scale_x_discrete("Treatment") + scale_y_discrete(name = "Adverse Event Term") + -->
<!--  theme_classic()+ -->
<!-- ggtitle("Heat Map for Number of Adverse Events per Treatment per Preferred Term for -->
<!-- Psychiatric Disorders") + theme(plot.title = element_text(hjust = 0.5)) + -->
<!--  labs(fill="Number of Events") -->
<!-- p3 -->
<p><img src="05-Plot-Adverse-Event_files/figure-html/unnamed-chunk-3-1.png" width="960" /></p>
<p><strong>HEAT MAP FOR NUMBER OF ADVERSE EVENTS OF PTS OF A SINGLE SOC
OF A SINGLE TREATMENT PER SEVERITY</strong></p>
<p>We can check the severity of all the PTs for a single SOC for a
single treatment. Let us analyze the Psychiatric Disorder PTs reported
for treatment Z. We will plot the number of events reported for PTs
against their severity which will have the value as Mild, Moderate or
Severe</p>
<p><img src="02_Plots/Visualization/AEs/AE_Heat%20Map%204.png" /></p>
<!-- sub1 <- subset(aeord,aeord$SOC=="PSYCHIATRIC" & TRTA=="Z") -->
<!-- tb5 <- aggregate(USUBJID~AEDECOD+AESEV, data=sub1, FUN=function(x) c(ln=length(x))) -->
<!-- names(tb5)[names(tb5)=="USUBJID"]<- "OBS" -->
<!-- p4 <- ggplot(tb5, aes(AESEV, AEDECOD, fill = OBS)) + geom_raster() + -->
<!-- geom_text(aes(label=paste0("N=",round(OBS,1)),color=OBS<10), show.legend = F,size=3)+ -->
<!-- scale_fill_gradient(low="yellow",high="red",na.value="white")+ -->
<!-- scale_color_manual(values = c("FALSE" = "white", "TRUE" = "black")) + -->
<!-- scale_x_discrete("Severity") + scale_y_discrete(name = "Adverse Event Term") + -->
<!-- theme_classic()+ ggtitle("Heat Map for Number of Adverse Events of PTs of Psychiatric -->
<!-- Disorders of Treatment Z per Severity") + theme(plot.title = element_text(hjust = -->
<!-- 0.5)) + labs(fill="Number of Events") -->
<!-- p4 -->
<p><strong>HEAT MAP FOR NUMBER OF RELATED AND NOT RELATED ADVERSE EVENTS
PER PT PER SEVERITY FOR A SINGLE TREATMENT</strong></p>
<p>We can check the causality of the events reported in the above plot
along with their severity. Let us once again consider the psychiatry PTs
reported for treatment Z. We will plot the number of events reported for
PTs with their causality which will have values as ‘Related’ or ‘Not
Related’ against severity</p>
<p><img src="02_Plots/Visualization/AEs/AE_Heat%20Map%205.png" /></p>
<!-- tb6 <- aggregate(USUBJID~AEDECOD+AESEV+AEREL, data=sub1, FUN=function(x) c(ln=length(x))) -->
<!-- names(tb6)[names(tb6)=="USUBJID"]<- "OBS" -->
<!-- tb6 <-tb6[order(tb6$AEDECOD,tb6$AESEV, tb6$OBS),] -->
<!-- p5 <- ggplot(tb6, aes(AESEV, AEDECOD, fill = OBS)) + geom_raster() + -->
<!-- geom_text(data=tb6[tb6$AEREL=="NOT RELATED",],aes(label=paste0("NREL=",round(OBS,1))), -->
<!-- show.legend = F,size=2.8, vjust=0, hjust=1) + -->
<!-- geom_text(data=tb6[tb6$AEREL=="RELATED",],aes(label = paste0("REL=",round(OBS, 1))), -->
<!-- show.legend = F,size=2.8, vjust=1, hjust=0)+ -->
<!-- scale_fill_gradient(low="yellow",high="red",na.value="white")+ -->
<!-- scale_x_discrete("Severity") + scale_y_discrete(name = "Adverse Event Term") + -->
<!-- theme_classic()+ -->
<!-- ggtitle("Heat Map for Number of Related and Not Related Adverse Events per PT per -->
<!-- Severity for Psychiatric Disorders of Treatment Z") + theme(plot.title = -->
<!-- element_text(hjust = 0.5)) + labs(fill="Number of Events") -->
<!-- p5 -->
<p><em>Source: <a
href="https://www.lexjansen.com/phuse/2018/dv/DV11.pdf"
class="uri">https://www.lexjansen.com/phuse/2018/dv/DV11.pdf</a></em></p>
</div>
<div id="volcano-plot" class="section level2">
<h2>Volcano Plot</h2>
<p>A volcano plot is a type of scatter-plot that is used to quickly
identify changes in large data sets composed of replicate data. It plots
significance versus fold-change on the y and x axes, respectively. It is
constructed by plotting the negative log of the p value on the y axis
(usually base 10). This results in data points with low p values (highly
significant) appearing toward the top of the plot. The x axis is the log
of the fold change between the two conditions. The log of the fold
change is used so that changes in both directions appear equidistant
from the center. In the clinical domain, a volcano plot is used to view
Risk Difference (RD), Relative Risk or Odds Ratio of AE occurrence
between the treatment groups by preferred term.</p>
<p><strong>VOLCANO PLOT OF TREATMENT EMERGENT ADVERSE EVENT AT PT
LEVEL</strong></p>
<p>Volcano plots are also generated on the same data which is used for
heat maps. Here, we have plotted negative log10-transformed p-value
calculated using Fisher exact test on Y-axis and Log2-transformed
relative risk on x-axis.</p>
<p>The dashed red line on y-axis shows where p = 0.05 with points above
the line having p &lt; 0.05 and points below the line having p &gt;
0.05. Note that smaller the p-value larger is the number on y-axis. For
this graph, we have labeled the AE terms with p-values &lt; 0.05 as they
are significant.</p>
<table class="table" style="color: black; margin-left: auto; margin-right: auto;">
<caption>
DATA SNIPPET
</caption>
<thead>
<tr>
<th style="text-align:left;">
AETERM
</th>
<th style="text-align:right;">
rr
</th>
<th style="text-align:right;">
log2rr
</th>
<th style="text-align:right;">
p
</th>
<th style="text-align:right;">
Total
</th>
<th style="text-align:left;">
term
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
NECK SHOULDER PAIN
</td>
<td style="text-align:right;">
1.7967074
</td>
<td style="text-align:right;">
1.7984807
</td>
<td style="text-align:right;">
0.0544522
</td>
<td style="text-align:right;">
13
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
SINUSITIS
</td>
<td style="text-align:right;">
4.7510003
</td>
<td style="text-align:right;">
-0.4996963
</td>
<td style="text-align:right;">
0.0594548
</td>
<td style="text-align:right;">
16
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
DECREASED APPETITE
</td>
<td style="text-align:right;">
2.5129638
</td>
<td style="text-align:right;">
2.4353532
</td>
<td style="text-align:right;">
0.0289871
</td>
<td style="text-align:right;">
33
</td>
<td style="text-align:left;">
DECREASED APPETITE
</td>
</tr>
<tr>
<td style="text-align:left;">
DRY MOUTH
</td>
<td style="text-align:right;">
5.3098027
</td>
<td style="text-align:right;">
0.6340520
</td>
<td style="text-align:right;">
0.0147967
</td>
<td style="text-align:right;">
43
</td>
<td style="text-align:left;">
DRY MOUTH
</td>
</tr>
<tr>
<td style="text-align:left;">
UPPER RESPIRATORY INFECTION
</td>
<td style="text-align:right;">
5.6487570
</td>
<td style="text-align:right;">
-1.5222139
</td>
<td style="text-align:right;">
0.0963061
</td>
<td style="text-align:right;">
46
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
COLD SYMPTOMS
</td>
<td style="text-align:right;">
0.3687833
</td>
<td style="text-align:right;">
1.0248390
</td>
<td style="text-align:right;">
0.0902397
</td>
<td style="text-align:right;">
8
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
DRYNESS IN MOUTH
</td>
<td style="text-align:right;">
3.2158224
</td>
<td style="text-align:right;">
2.5189308
</td>
<td style="text-align:right;">
0.0691015
</td>
<td style="text-align:right;">
10
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
WEIGHT GAIN
</td>
<td style="text-align:right;">
5.3652724
</td>
<td style="text-align:right;">
2.4190755
</td>
<td style="text-align:right;">
0.0795672
</td>
<td style="text-align:right;">
42
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
HYPERHIDROSIS
</td>
<td style="text-align:right;">
3.3534666
</td>
<td style="text-align:right;">
2.0661030
</td>
<td style="text-align:right;">
0.0025589
</td>
<td style="text-align:right;">
11
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
INCREASED IRRITABILITY
</td>
<td style="text-align:right;">
2.7940269
</td>
<td style="text-align:right;">
1.9556811
</td>
<td style="text-align:right;">
0.0478318
</td>
<td style="text-align:right;">
24
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
INCREASED THIRST
</td>
<td style="text-align:right;">
5.7453167
</td>
<td style="text-align:right;">
2.5768103
</td>
<td style="text-align:right;">
0.0758701
</td>
<td style="text-align:right;">
28
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
LOWER BACK PAIN
</td>
<td style="text-align:right;">
2.7746715
</td>
<td style="text-align:right;">
1.9886535
</td>
<td style="text-align:right;">
0.0217192
</td>
<td style="text-align:right;">
8
</td>
<td style="text-align:left;">
NA
</td>
</tr>
<tr>
<td style="text-align:left;">
NUMBNESS (BOTH HANDS)
</td>
<td style="text-align:right;">
4.0976667
</td>
<td style="text-align:right;">
2.0977219
</td>
<td style="text-align:right;">
0.0318863
</td>
<td style="text-align:right;">
28
</td>
<td style="text-align:left;">
NA
</td>
</tr>
</tbody>
</table>
<p><img src="05-Plot-Adverse-Event_files/figure-html/unnamed-chunk-4-1.png" width="960" /></p>
</div>
<div id="bubble-plot" class="section level2">
<h2>Bubble Plot</h2>
<p><strong>BUBBLE PLOT OF -LOG10 (P-VALUE) BY RELATIVE RISK SIZED BY
COUNTS</strong></p>
<p>The x-axis represents the log2 relative risk and y-axis represents
the –log10 p-values computed using the fisher exact test. Each bubble
represents an adverse event, with bubble size indicative of the total
number of adverse events that occur for both treatments combined.
Specifically, the bubble area is proportional to the total number of
events.</p>
<p>Log2 (Relative Risk) of 0 represents no difference in risk between
the 2 treatment groups, while bubbles to the right indicate a higher
risk for subjects in treatment group Y (i.e. – If Log2 (RR) = 1, that is
the same as an RR=2), and bubbles to the left indicate a higher risk for
subjects in treatment group Z. Color, green and blue helps to emphasize
adverse events that are more common for treatment Y or Z, respectively.
The size of the bubble represents the total number of occurrences of the
AE of interest. Names of events with total number of occurrences greater
than 10 are displayed.</p>
<div class="plotly html-widget html-fill-item" id="htmlwidget-dfa5d821dc44474b3e8c" style="width:960px;height:576px;"></div>
<script type="application/json" data-for="htmlwidget-dfa5d821dc44474b3e8c">{"x":{"visdat":{"24146a764722":["function () ","plotlyVisDat"]},"cur_data":"24146a764722","attrs":{"24146a764722":{"x":{},"y":{},"text":{},"mode":"markers","marker":{"size":{},"opacity":0.90000000000000002},"color":{},"colors":["blue","green"],"alpha_stroke":1,"sizes":[10,100],"spans":[1,20],"type":"scatter"}},"layout":{"margin":{"b":40,"l":60,"t":25,"r":10},"title":"Bubble Plot Treatment Emergent Adverse Event of Significance versus Relative<br />Risk","xaxis":{"domain":[0,1],"automargin":true,"showgrid":false,"title":"Log2 (Relative Risk)"},"yaxis":{"domain":[0,1],"automargin":true,"showgrid":false,"title":"-Log10 (p-value)"},"annotations":[{"text":null,"x":1.7984806959087485,"y":1.2639846019611922,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}},{"text":null,"x":-0.49969634350375841,"y":1.225813166277796,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}},{"text":"DECREASED APPETITE","x":2.4353531824483436,"y":1.5377958641655511,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}},{"text":"DRY MOUTH","x":0.63405198918775807,"y":1.8298365000665657,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}},{"text":null,"x":-1.522213900615502,"y":1.016346109984575,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}},{"text":null,"x":1.0248389586175237,"y":1.0446024793675117,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}},{"text":null,"x":2.5189307633519533,"y":1.160512793480508,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}},{"text":null,"x":2.4190755272227609,"y":1.0992659518018075,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}},{"text":null,"x":2.0661030045451168,"y":2.5919454836768852,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}},{"text":null,"x":1.9556811314634255,"y":1.320283116504829,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}},{"text":null,"x":2.5768103293901206,"y":1.119929298876813,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}},{"text":null,"x":1.9886535023326743,"y":1.6631571195022936,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}},{"text":null,"x":2.0977219480164111,"y":1.4963961083258459,"xref":"x","yref":"y","showarrow":false,"font":{"size":10}}],"hovermode":"closest","showlegend":false,"legend":{"yanchor":"top","y":0.5}},"source":"A","config":{"modeBarButtonsToAdd":["hoverclosest","hovercompare"],"showSendToCloud":false},"data":[{"x":[1.7984806959087485,-0.49969634350375841,2.4353531824483436,0.63405198918775807,-1.522213900615502,1.0248389586175237,2.5189307633519533,2.4190755272227609,2.0661030045451168,1.9556811314634255,2.5768103293901206,1.9886535023326743,2.0977219480164111],"y":[1.2639846019611922,1.225813166277796,1.5377958641655511,1.8298365000665657,1.016346109984575,1.0446024793675117,1.160512793480508,1.0992659518018075,2.5919454836768852,1.320283116504829,1.119929298876813,1.6631571195022936,1.4963961083258459],"text":["NECK SHOULDER PAIN","SINUSITIS","DECREASED APPETITE","DRY MOUTH","UPPER RESPIRATORY INFECTION","COLD SYMPTOMS","DRYNESS IN MOUTH","WEIGHT GAIN","HYPERHIDROSIS","INCREASED IRRITABILITY","INCREASED THIRST","LOWER BACK PAIN","NUMBNESS (BOTH HANDS)"],"mode":"markers","marker":{"colorbar":{"title":"log2rr","ticklen":2},"cmin":-1.522213900615502,"cmax":2.5768103293901206,"colorscale":[["0","rgba(0,0,255,1)"],["0.0416666666666667","rgba(49,29,248,1)"],["0.0833333333333334","rgba(69,45,241,1)"],["0.125","rgba(83,58,233,1)"],["0.166666666666667","rgba(93,70,226,1)"],["0.208333333333333","rgba(102,81,219,1)"],["0.25","rgba(108,91,211,1)"],["0.291666666666667","rgba(113,101,204,1)"],["0.333333333333333","rgba(118,110,197,1)"],["0.375","rgba(121,120,189,1)"],["0.416666666666667","rgba(123,129,182,1)"],["0.458333333333333","rgba(125,138,174,1)"],["0.5","rgba(125,147,166,1)"],["0.541666666666667","rgba(125,156,158,1)"],["0.583333333333333","rgba(124,165,150,1)"],["0.625","rgba(123,174,141,1)"],["0.666666666666667","rgba(120,183,133,1)"],["0.708333333333333","rgba(116,192,124,1)"],["0.75","rgba(111,201,114,1)"],["0.791666666666667","rgba(105,210,104,1)"],["0.833333333333333","rgba(97,219,92,1)"],["0.875","rgba(87,228,79,1)"],["0.916666666666667","rgba(73,237,64,1)"],["0.958333333333333","rgba(52,246,44,1)"],["1","rgba(0,255,0,1)"]],"showscale":false,"color":[1.7984806959087485,-0.49969634350375841,2.4353531824483436,0.63405198918775807,-1.522213900615502,1.0248389586175237,2.5189307633519533,2.4190755272227609,2.0661030045451168,1.9556811314634255,2.5768103293901206,1.9886535023326743,2.0977219480164111],"size":[13,16,33,43,46,8,10,42,11,24,28,8,28],"opacity":0.90000000000000002,"line":{"colorbar":{"title":"","ticklen":2},"cmin":-1.522213900615502,"cmax":2.5768103293901206,"colorscale":[["0","rgba(0,0,255,1)"],["0.0416666666666667","rgba(49,29,248,1)"],["0.0833333333333334","rgba(69,45,241,1)"],["0.125","rgba(83,58,233,1)"],["0.166666666666667","rgba(93,70,226,1)"],["0.208333333333333","rgba(102,81,219,1)"],["0.25","rgba(108,91,211,1)"],["0.291666666666667","rgba(113,101,204,1)"],["0.333333333333333","rgba(118,110,197,1)"],["0.375","rgba(121,120,189,1)"],["0.416666666666667","rgba(123,129,182,1)"],["0.458333333333333","rgba(125,138,174,1)"],["0.5","rgba(125,147,166,1)"],["0.541666666666667","rgba(125,156,158,1)"],["0.583333333333333","rgba(124,165,150,1)"],["0.625","rgba(123,174,141,1)"],["0.666666666666667","rgba(120,183,133,1)"],["0.708333333333333","rgba(116,192,124,1)"],["0.75","rgba(111,201,114,1)"],["0.791666666666667","rgba(105,210,104,1)"],["0.833333333333333","rgba(97,219,92,1)"],["0.875","rgba(87,228,79,1)"],["0.916666666666667","rgba(73,237,64,1)"],["0.958333333333333","rgba(52,246,44,1)"],["1","rgba(0,255,0,1)"]],"showscale":false,"color":[1.7984806959087485,-0.49969634350375841,2.4353531824483436,0.63405198918775807,-1.522213900615502,1.0248389586175237,2.5189307633519533,2.4190755272227609,2.0661030045451168,1.9556811314634255,2.5768103293901206,1.9886535023326743,2.0977219480164111]}},"type":"scatter","xaxis":"x","yaxis":"y","frame":null},{"x":[-1.522213900615502,2.5768103293901206],"y":[1.016346109984575,2.5919454836768852],"type":"scatter","mode":"markers","opacity":0,"hoverinfo":"none","showlegend":false,"marker":{"colorbar":{"title":"log2rr","ticklen":2,"len":0.5,"lenmode":"fraction","y":1,"yanchor":"top"},"cmin":-1.522213900615502,"cmax":2.5768103293901206,"colorscale":[["0","rgba(0,0,255,1)"],["0.0416666666666667","rgba(49,29,248,1)"],["0.0833333333333334","rgba(69,45,241,1)"],["0.125","rgba(83,58,233,1)"],["0.166666666666667","rgba(93,70,226,1)"],["0.208333333333333","rgba(102,81,219,1)"],["0.25","rgba(108,91,211,1)"],["0.291666666666667","rgba(113,101,204,1)"],["0.333333333333333","rgba(118,110,197,1)"],["0.375","rgba(121,120,189,1)"],["0.416666666666667","rgba(123,129,182,1)"],["0.458333333333333","rgba(125,138,174,1)"],["0.5","rgba(125,147,166,1)"],["0.541666666666667","rgba(125,156,158,1)"],["0.583333333333333","rgba(124,165,150,1)"],["0.625","rgba(123,174,141,1)"],["0.666666666666667","rgba(120,183,133,1)"],["0.708333333333333","rgba(116,192,124,1)"],["0.75","rgba(111,201,114,1)"],["0.791666666666667","rgba(105,210,104,1)"],["0.833333333333333","rgba(97,219,92,1)"],["0.875","rgba(87,228,79,1)"],["0.916666666666667","rgba(73,237,64,1)"],["0.958333333333333","rgba(52,246,44,1)"],["1","rgba(0,255,0,1)"]],"showscale":true,"color":[-1.522213900615502,2.5768103293901206],"line":{"color":"rgba(255,127,14,1)"}},"xaxis":"x","yaxis":"y","frame":null}],"highlight":{"on":"plotly_click","persistent":false,"dynamic":false,"selectize":false,"opacityDim":0.20000000000000001,"selected":{"opacity":1},"debounce":0},"shinyEvents":["plotly_hover","plotly_click","plotly_selected","plotly_relayout","plotly_brushed","plotly_brushing","plotly_clickannotation","plotly_doubleclick","plotly_deselect","plotly_afterplot","plotly_sunburstclick"],"base_url":"https://plot.ly"},"evals":[],"jsHooks":[]}</script>
</div>
<div id="tendril-plot" class="section level2">
<h2>Tendril Plot</h2>
<p>The Tendril plot concept is illustrated using the preferred term of
Back Pain. Events on placebo tilt the tendril to the right and events on
active tilt the tendril to the left. In this illustrative plot, events
are colored by treatment arm; yellow and brown circles for placebo and
active arm, respectively. The distance between points are proportional
to time between events.</p>
<p><img src="02_Plots/Visualization/AEs/AE_Tendril_Intro.png" /></p>
<p><a href="https://steve-mallett.shinyapps.io/TendrilPlot/">Tendril
Plot Shiny App</a></p>
<p>This tendril plot provides a visual comparison of System Organ Class
Adverse Events (AEs) between a placebo group and an intervention group
in a clinical study. Each tendril represents a different category of
AEs, such as gastrointestinal or neurological, differentiated by color.
The plot’s horizontal axis divides the two study groups, while the
vertical axis indicates the progression of the study, though specific
time units are not provided.</p>
<p>In the plot, the length and direction of each tendril illustrate the
incidence and progression of AEs in each category relative to the
treatment group. For example, lines extending significantly toward the
intervention side indicate a higher occurrence of AEs in that group
compared to placebo. This visual tool is effective for quickly assessing
the safety profile and identifying the most prevalent adverse events in
each treatment group during the study.</p>
<p><img src="02_Plots/Visualization/AEs/AE_Tendril.png" /></p>
</div>
<div id="double-dot-plot" class="section level2">
<h2>Double Dot Plot</h2>
<p><img src="02_Plots/Visualization/ForestPlot/DoubleDot.png" /></p>
<p><img src="05-Plot-Adverse-Event_files/figure-html/unnamed-chunk-6-1.png" width="960" /></p>
</div>
<div id="highest-reported-adverse-events" class="section level2">
<h2>10 Highest Reported Adverse Events</h2>
<p><img src="05-Plot-Adverse-Event_files/figure-html/unnamed-chunk-8-1.png" width="960" /></p>
<hr />
<div id="adverse-events-by-sex" class="section level3">
<h3>Adverse Events By Sex</h3>
<div id="soxqwkgowz" style="padding-left:0px;padding-right:0px;padding-top:10px;padding-bottom:10px;overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>#soxqwkgowz table {
  font-family: system-ui, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol', 'Noto Color Emoji';
  -webkit-font-smoothing: antialiased;
  -moz-osx-font-smoothing: grayscale;
}

#soxqwkgowz thead, #soxqwkgowz tbody, #soxqwkgowz tfoot, #soxqwkgowz tr, #soxqwkgowz td, #soxqwkgowz th {
  border-style: none;
}

#soxqwkgowz p {
  margin: 0;
  padding: 0;
}

#soxqwkgowz .gt_table {
  display: table;
  border-collapse: collapse;
  line-height: normal;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#soxqwkgowz .gt_caption {
  padding-top: 4px;
  padding-bottom: 4px;
}

#soxqwkgowz .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#soxqwkgowz .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 3px;
  padding-bottom: 5px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#soxqwkgowz .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#soxqwkgowz .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#soxqwkgowz .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#soxqwkgowz .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#soxqwkgowz .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#soxqwkgowz .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#soxqwkgowz .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#soxqwkgowz .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#soxqwkgowz .gt_spanner_row {
  border-bottom-style: hidden;
}

#soxqwkgowz .gt_group_heading {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  text-align: left;
}

#soxqwkgowz .gt_empty_group_heading {
  padding: 0.5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#soxqwkgowz .gt_from_md > :first-child {
  margin-top: 0;
}

#soxqwkgowz .gt_from_md > :last-child {
  margin-bottom: 0;
}

#soxqwkgowz .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#soxqwkgowz .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
}

#soxqwkgowz .gt_stub_row_group {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 5px;
  padding-right: 5px;
  vertical-align: top;
}

#soxqwkgowz .gt_row_group_first td {
  border-top-width: 2px;
}

#soxqwkgowz .gt_row_group_first th {
  border-top-width: 2px;
}

#soxqwkgowz .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#soxqwkgowz .gt_first_summary_row {
  border-top-style: solid;
  border-top-color: #D3D3D3;
}

#soxqwkgowz .gt_first_summary_row.thick {
  border-top-width: 2px;
}

#soxqwkgowz .gt_last_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#soxqwkgowz .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#soxqwkgowz .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#soxqwkgowz .gt_last_grand_summary_row_top {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-bottom-style: double;
  border-bottom-width: 6px;
  border-bottom-color: #D3D3D3;
}

#soxqwkgowz .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#soxqwkgowz .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#soxqwkgowz .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#soxqwkgowz .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

#soxqwkgowz .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#soxqwkgowz .gt_sourcenote {
  font-size: 90%;
  padding-top: 4px;
  padding-bottom: 4px;
  padding-left: 5px;
  padding-right: 5px;
}

#soxqwkgowz .gt_left {
  text-align: left;
}

#soxqwkgowz .gt_center {
  text-align: center;
}

#soxqwkgowz .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#soxqwkgowz .gt_font_normal {
  font-weight: normal;
}

#soxqwkgowz .gt_font_bold {
  font-weight: bold;
}

#soxqwkgowz .gt_font_italic {
  font-style: italic;
}

#soxqwkgowz .gt_super {
  font-size: 65%;
}

#soxqwkgowz .gt_footnote_marks {
  font-size: 75%;
  vertical-align: 0.4em;
  position: initial;
}

#soxqwkgowz .gt_asterisk {
  font-size: 100%;
  vertical-align: 0;
}

#soxqwkgowz .gt_indent_1 {
  text-indent: 5px;
}

#soxqwkgowz .gt_indent_2 {
  text-indent: 10px;
}

#soxqwkgowz .gt_indent_3 {
  text-indent: 15px;
}

#soxqwkgowz .gt_indent_4 {
  text-indent: 20px;
}

#soxqwkgowz .gt_indent_5 {
  text-indent: 25px;
}

#soxqwkgowz .katex-display {
  display: inline-flex !important;
  margin-bottom: 0.75em !important;
}

#soxqwkgowz div.Reactable > div.rt-table > div.rt-thead > div.rt-tr.rt-tr-group-header > div.rt-th-group:after {
  height: 0px !important;
}
</style>
<table class="gt_table" data-quarto-disable-processing="false" data-quarto-bootstrap="false">
  <thead>
    <tr class="gt_heading">
      <td colspan="4" class="gt_heading gt_title gt_font_normal" style><span class='gt_from_md'>Adverse Events</span></td>
    </tr>
    <tr class="gt_heading">
      <td colspan="4" class="gt_heading gt_subtitle gt_font_normal gt_bottom_border" style>The top ten most reported events</td>
    </tr>
    <tr class="gt_col_headings gt_spanner_row">
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="2" colspan="1" scope="col" id="a::stub">Patient Reaction</th>
      <th class="gt_center gt_columns_top_border gt_column_spanner_outer" rowspan="1" colspan="2" scope="colgroup" id="By sex">
        <div class="gt_column_spanner">By sex</div>
      </th>
      <th class="gt_center gt_columns_top_border gt_column_spanner_outer" rowspan="1" colspan="1" scope="col" id="Total Cases">
        <div class="gt_column_spanner">Total Cases</div>
      </th>
    </tr>
    <tr class="gt_col_headings">
      <th class="gt_col_heading gt_columns_bottom_border gt_right" rowspan="1" colspan="1" scope="col" id="female">Female</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_right" rowspan="1" colspan="1" scope="col" id="male">Male</th>
      <th class="gt_col_heading gt_columns_bottom_border gt_right" rowspan="1" colspan="1" scope="col" id="Total"></th>
    </tr>
  </thead>
  <tbody class="gt_table_body">
    <tr><th id="stub_1_1" scope="row" class="gt_row gt_left gt_stub">Malignant Neoplasm Progression</th>
<td headers="stub_1_1 female" class="gt_row gt_right">3,829</td>
<td headers="stub_1_1 male" class="gt_row gt_right">4,627</td>
<td headers="stub_1_1 Total" class="gt_row gt_right">8,456</td></tr>
    <tr><th id="stub_1_2" scope="row" class="gt_row gt_left gt_stub">Death</th>
<td headers="stub_1_2 female" class="gt_row gt_right">1,667</td>
<td headers="stub_1_2 male" class="gt_row gt_right">2,353</td>
<td headers="stub_1_2 Total" class="gt_row gt_right">4,020</td></tr>
    <tr><th id="stub_1_3" scope="row" class="gt_row gt_left gt_stub">Diarrhoea</th>
<td headers="stub_1_3 female" class="gt_row gt_right">2,106</td>
<td headers="stub_1_3 male" class="gt_row gt_right">1,717</td>
<td headers="stub_1_3 Total" class="gt_row gt_right">3,823</td></tr>
    <tr><th id="stub_1_4" scope="row" class="gt_row gt_left gt_stub">Off Label Use</th>
<td headers="stub_1_4 female" class="gt_row gt_right">1,462</td>
<td headers="stub_1_4 male" class="gt_row gt_right">1,709</td>
<td headers="stub_1_4 Total" class="gt_row gt_right">3,171</td></tr>
    <tr><th id="stub_1_5" scope="row" class="gt_row gt_left gt_stub">Fatigue</th>
<td headers="stub_1_5 female" class="gt_row gt_right">2,110</td>
<td headers="stub_1_5 male" class="gt_row gt_right">1,540</td>
<td headers="stub_1_5 Total" class="gt_row gt_right">3,650</td></tr>
    <tr><th id="stub_1_6" scope="row" class="gt_row gt_left gt_stub">Product Use In Unapproved Indication</th>
<td headers="stub_1_6 female" class="gt_row gt_right">1,428</td>
<td headers="stub_1_6 male" class="gt_row gt_right">1,389</td>
<td headers="stub_1_6 Total" class="gt_row gt_right">2,817</td></tr>
    <tr><th id="stub_1_7" scope="row" class="gt_row gt_left gt_stub">Pyrexia</th>
<td headers="stub_1_7 female" class="gt_row gt_right">1,472</td>
<td headers="stub_1_7 male" class="gt_row gt_right">1,233</td>
<td headers="stub_1_7 Total" class="gt_row gt_right">2,705</td></tr>
    <tr><th id="stub_1_8" scope="row" class="gt_row gt_left gt_stub">Decreased Appetite</th>
<td headers="stub_1_8 female" class="gt_row gt_right">1,164</td>
<td headers="stub_1_8 male" class="gt_row gt_right">1,092</td>
<td headers="stub_1_8 Total" class="gt_row gt_right">2,256</td></tr>
    <tr><th id="stub_1_9" scope="row" class="gt_row gt_left gt_stub">Rash</th>
<td headers="stub_1_9 female" class="gt_row gt_right">1,229</td>
<td headers="stub_1_9 male" class="gt_row gt_right">1,076</td>
<td headers="stub_1_9 Total" class="gt_row gt_right">2,305</td></tr>
    <tr><th id="stub_1_10" scope="row" class="gt_row gt_left gt_stub">Nausea</th>
<td headers="stub_1_10 female" class="gt_row gt_right">1,615</td>
<td headers="stub_1_10 male" class="gt_row gt_right">843</td>
<td headers="stub_1_10 Total" class="gt_row gt_right">2,458</td></tr>
  </tbody>
  <tfoot class="gt_sourcenotes">
    <tr>
      <td class="gt_sourcenote" colspan="4">All data queried from openFDA</td>
    </tr>
  </tfoot>
  
</table>
</div>
</div>
</div>
</div>
<div id="reference" class="section level1">
<h1>Reference</h1>
<ul>
<li><a
href="https://www.linkedin.com/pulse/most-frequent-ae-relative-risk-using-r-jagadish-katam/?trackingId=GllB04d3RAe%2BIPwtx1czFg%3D%3D">Most
Frequent AE by Relative Risk/Forest Plot using</a></li>
<li><a href="https://www.lexjansen.com/phuse/2018/dv/DV11.pdf">Adverse
Event Data – gRaphically</a></li>
<li>SIG (2024, Feb. 8). VIS-SIG Blog: Wonderful Wednesdays February
2024. Retrieved from <a
href="https://graphicsprinciples.github.io/posts/2024-09-01-wonderful-wednesdays-february-2024/"
class="uri">https://graphicsprinciples.github.io/posts/2024-09-01-wonderful-wednesdays-february-2024/</a></li>
</ul>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
